| Project/Area Number |
18K16269
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | National Cancer Center Japan (2020)
Waseda University (2018-2019) |
|---|
Principal Investigator |
Nakayama Jun 国立研究開発法人国立がん研究センター, 研究所, 外来研究員(特別研究員PD) (30801237)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ERBB2 / 乳癌 / 遺伝子増幅 / がん転移 / 多臓器転移 / ホメオボックス遺伝子 / アンプリコン / HER2陽性乳がん / RNA-seq / 転移 / 転写因子 / がん遺伝子 |
|---|
| Outline of Final Research Achievements |
Gene Amplification of ERBB2(HER2) is important as a diagnostic and therapeutic target for cancer. However, the implication of co-amplification of ERBB2 neighbor 50 genes remains unclear.
As a result of this study, HNF1B, located at the margin of ERBB2 amplicon, induced multi-organ metastasis in breast cancer. In addition, RNA-seq analysis of tumor cells isolated from metastatic tissue revealed that in vivo selection occurred when the cells were transplanted into the mammary fatpad. Furthermore, we succeeded in extracting genes that are characteristically expressed in each of the primary and metastatic lesions.
|
| Academic Significance and Societal Importance of the Research Achievements |
乳癌におけるがん遺伝子であるERBB2（HER2）は遺伝子増幅によって遺伝子のコピー数が増大している。このERBB2の遺伝子増幅は癌の診断・治療標的として重要視されてきたが、ERBB2近傍の50にもおよぶ遺伝子群も共に遺伝子増幅されることの意義はほとんど明らかになっていない。ERBB2アンプリコン（17q12.21）に含まれる遺伝子が乳癌遠隔転移においてどのような役割をもつか明らかにすることで、乳癌におけるアンプリコン領域長の治療・診断への応用が期待できる。
|
